Direct factory bulk supply with full CoA, HPLC analytical verification, and regulatory dossier support.
In-depth analysis of metabolic therapeutics, peptide synthesis technology, and bulk API supply chain architecture.
The global healthcare, metabolic management, and biopharmaceutical sectors are undergoing a historical paradigm shift. Driven by breakthroughs in incretin-based mimetic therapies, the demand for commercial-scale, high-purity wholesale health care and weight loss raw materials has reached unprecedented levels. Modern pharmaceutical development has transitioned from broad non-specific metabolic agents toward targeted peptide Active Pharmaceutical Ingredients (APIs), including GLP-1 (Glucagon-Like Peptide-1), GIP (Glucose-Dependent Insulinotropic Polypeptide), and GCGR (Glucagon Receptor) multi-agonists such as Tirzepatide, Retatrutide, and Cagrilintide.
As a leading primary manufacturer and global supplier, Gentolex Group operates at the forefront of this industrial evolution. With an overall state-of-the-art factory construction area spanning 250,000 square meters engineered under strict international standards, we deliver scalable, robust, and cost-effective raw material synthesis solutions. Our core expertise encompasses solid-phase peptide synthesis (SPPS), liquid-phase synthesis (LPPS), custom chemical intermediates, and Finished Dosage Form (FDF) licensing out.
Gentolex’s goal is to create seamless opportunities connecting global pharmaceutical formulators, compounding facilities, research institutions, and health brand owners with fully verified products and technical end-to-end support. Up to date, Gentolex Group serves clientele across more than 10 countries, backed by established strategic representative operations in Mexico and South Africa.
Over 250,000 m² of specialized production area providing high-volume chemical building blocks, industrial solvents like N,N-Dimethylacetamide (DMAC), plasticizers, and noble metal catalysts (Rhodium III Nitrate) under precise reaction parameters.
Extensive catalog of small-molecule APIs and complex peptide therapeutics manufactured following cGMP guidelines. Full supporting analytical dossiers including HPLC, MS, NMR, CoA, and stability data.
Eliminating multi-vendor complexities via single-point consolidated sourcing. Custom chemical synthesis, OEM vial lyophilization, laboratory setup consultation, and FDF license-out partnerships.
Why leading global healthcare brands and pharmaceutical enterprises partner with Chinese chemical & peptide manufacturing hubs.
China possesses the world's most comprehensive industrial chemical ecosystem. From basic precursor chemicals (e.g., Boc-His(Trt)-Aib-Glu(OtBu)-Gly-OH protective amino acid building blocks) to advanced peptide purification columns, complete raw material autonomy minimizes supply chain disruption risks and reduces cost structures by 35-50% compared to Western counterparts.
Gentolex's manufacturing units utilize computer-controlled automated Solid-Phase Peptide Synthesizers combined with large-scale industrial prep-HPLC purification units. This enables seamless scaling from gram-level pilot batches to multi-kilogram commercial batches with batch-to-batch consistency exceeding 99% purity.
Quality reliability is non-negotiable. Modern Chinese chemical export facilities operate under ISO 9001, ISO 14001, and cGMP-aligned Quality Management Systems (QMS). Every batch undergoes rigorous analytical testing: High-Performance Liquid Chromatography (HPLC), Mass Spectrometry (LC-MS), Karl Fischer water content analysis, Endotoxin testing, and Heavy Metal ICP-MS screening.
We provide tailored OEM packaging, custom lyophilized vial filling (2mg, 5mg, 10mg, 20mg), and private labeling options. Supported by validated cold-chain logistics hubs (2-8°C and -20°C ambient controls), we ensure swift, compliant global delivery to North America, Europe, Latin America, and Africa.
Scientific breakdown of core peptides, APIs, and specialized organic intermediates engineered by Gentolex.
| Raw Material / API Name | CAS Number / Sequence | Primary Therapeutic Application | Standard Purity Grade | Available Form Factors |
|---|---|---|---|---|
| Tirzepatide | 2023788-19-2 | Dual GLP-1/GIP Receptor Agonist, Anti-Obesity, Type 2 Diabetes | ≥ 99.0% (HPLC) | Lyophilized Powder, Bulk API |
| Retatrutide | 2381089-83-2 | Triple Agonist (GLP-1 / GIP / GCGR), Advanced Weight Loss | ≥ 99.0% (HPLC) | Vials (20mg), Custom Bulk Vials |
| Cagrilintide | 1415456-99-3 | Long-Acting Amylin Analogue, Synergistic Weight Management | ≥ 98.5% (HPLC) | Lyophilized Powder |
| BPC-157 | 137525-51-0 | Cytoprotective Pentadecapeptide, Tissue Repair & Gut Health | ≥ 98.0% (HPLC) | 5mg / 10mg Lyophilized Vials |
| MOTS-C | 1627580-64-6 | Mitochondrial-Derived Peptide, Metabolic Rate Regulation | ≥ 98.0% (HPLC) | 5mg Lyophilized Vials |
| Ergothioneine | 497-30-3 | Master Antioxidant, Cellular Protection & Anti-Aging | ≥ 99.0% (HPLC) | Crystalline Powder |
| Sildenafil Citrate | 171599-83-0 | PDE5 Inhibitor, Erectile Dysfunction & Vascular Support | USP / EP / IP Grade | Micronized Bulk API Powder |
| DMAC (N,N-Dimethylacetamide) | 127-19-5 | High-Purity Industrial Reaction Solvent & API Intermediate | ≥ 99.9% (GC) | 200L Drums, IBC Totes |
Empowering compounders, pharmaceutical formulators, and global wellness enterprise brands.
With global demand for injectable weight-management solutions soaring, licensed 503A and 503B compounding pharmacies rely on our sterile-ready, high-purity Tirzepatide, Retatrutide, and Cagrilintide APIs to formulate customized patient-specific therapies.
Nutraceutical and wellness brands integrate mitochondrial bioactive peptides like MOTS-C and SS-31 alongside antioxidants such as Ergothioneine into novel anti-obesity formulations aimed at muscle preservation during rapid fat loss cycles.
Gentolex offers complete Finished Dosage Form (FDF) licensing out, enabling regional pharmaceutical firms to fast-track market entry without expanding in-house capital expenditure or navigating multi-year synthesis R&D cycles.
Gentolex’s overarching mission is to bridge global healthcare demands with world-class manufacturing excellence, guaranteed product purity, and unmatched supply chain security. Serving clients in over 10 countries with physical representative hubs in Mexico and South Africa, Gentolex is a recognized leader in peptide API manufacturing and chemical sourcing.
Our dedicated facilities span 250,000 m², housing advanced analytical laboratories, pilot plants, and commercial-scale production lines operating under strict international cGMP standards.
Deep-dive research articles into neuroactive peptides, tissue regeneration compounds, and metabolic active ingredients.
Selank Acetate API is a synthetic heptapeptide active pharmaceutical ingredient composed of the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). Originally developed through neuropharmacological research, Selank represents a breakthrough derivative of endogenous Tuftsin...
Read Full Research Paper →
As a professional Thymosin Beta-4 API manufacturer and supplier, we deliver validated high-purity Thymosin Beta-4 peptide API solutions for global biotechnology companies, pharmaceutical research organizations, and regenerative medicine studies...
Read Full Research Paper →
BPC-157 API is a synthetic pentadecapeptide that has gained widespread global attention in peptide research due to its biological activities related to rapid tissue repair, gastrointestinal tract mucosal protection, and angiogenesis regulation...
Read Full Research Paper →
With continuous developments in neuroscience and peptide technology, neuroactive peptides are pivotal in life sciences. Semax, derived from an ACTH fragment, exhibits high metabolic stability and neuroprotective target binding...
Read Full Research Paper →
SS-31 API, also known as Elamipretide, MTP-131, and Bendavia, is a synthetic mitochondria-targeting tetrapeptide engineered to bind cardiolipin in the inner mitochondrial membrane, supporting bioenergetics and reducing cellular oxidative stress...
Read Full Research Paper →Critical strategic insights for pharmaceutical buyers, CDMO procurement officers, and brand executives.
The market for metabolic management has evolved rapidly beyond single-target GLP-1 mimetics (such as Semaglutide). Dual GLP-1/GIP agonists like Tirzepatide and triple agonists (GLP-1/GIP/Glucagon receptor) like Retatrutide represent the current peak of clinical efficacy, driving average weight reductions exceeding 24% in clinical trials. Procurement teams must partner with manufacturers capable of synthesizing complex multi-peptide sequences with high stereospecific fidelity.
Regulatory authorities including the US FDA, EMA, and NMPA have significantly tightened acceptable residual solvent and impurity thresholds for peptide APIs. Advanced manufacturers must implement specialized counter-ion conversion techniques to replace TFA salts with acetate or hydrochloride salts, ensuring superior biocompatibility and extended shelf life stability in final liquid or lyophilized dosage forms.
Recent global logistics disruptions highlight the risk of relying on multi-tiered chemical supply chains. Gentolex maintains backward integration into protected amino acid starting materials (such as Boc-His(Trt)-Aib-Glu(OtBu)-Gly-OH), guaranteeing uninterrupted commercial scale production even during global raw material shortages.
Answers to common technical, regulatory, procurement, and shipping queries from global enterprise buyers.
All our wholesale weight loss peptide APIs, including Tirzepatide and Retatrutide, are manufactured to high analytical standards with HPLC purity levels strictly verified at ≥ 99.0%. Complete analytical data including LC-MS, HPLC chromatograms, Certificate of Analysis (CoA), and Heavy Metal screening are provided with every batch order.
Yes. We provide complete OEM/ODM turnkey solutions. Our sterile cleanroom facilities support lyophilized vial filling across various standard dosages (e.g., 2mg, 5mg, 10mg, 20mg vials), customized flip-off cap colors, custom box packaging, and private label branding to match your commercial specifications.
Operating out of a 250,000 square meter factory complex, our capacity ranges from gram-scale pilot synthesis for research customers to commercial multi-kilogram API production. MOQ depends on the specific raw material: standard lyophilized vials start at 10–50 vials, while bulk chemical APIs start at 1kg.
We utilize validated temperature-monitored cold-chain shipping protocols (ice packs, gel packs, or dry ice containers where necessary) to maintain structural integrity during transit. We have extensive export experience delivering seamlessly to North America, Europe, Latin America, Africa, and Asia with full customs clearing expertise.
Browse our expanded portfolio of certified peptides, fine chemical intermediates, and organic active ingredients.
